If you or a loved one are on Tysabri and concerned about PML, you may have heard of symptoms like confusion, vision changes, or weakness. These patterns have been documented in medical literature for decades, forming a recognized body of pharmacovigilance knowledge. This page reviews the clinical signals reported in published cases to help you understand what to watch for.
The pivot to occupational exposure concern centers on the question of timing and legal recourse. For those who have taken Tysabri and later developed PML, understanding the statute of limitations in Washington becomes paramount. This legal timeframe dictates how long an affected individual has to seek legal representation and file a claim. Thus, the transition from general health information to a targeted legal inquiry about Tysabri exposure and PML risk is both necessary and timely, bridging public health knowledge with individual legal rights. Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, leading to demyelination and progressive neurological deterioration. The clinical presentation of PML typically includes subacute onset of focal neurological deficits such as weakness, gait disturbance, cognitive impairment, visual field defects, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The disease course is often rapid, with severe disability or death occurring within months of symptom onset in many cases. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of lymphocytes, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. The drug's immunosuppressive effect on the brain microenvironment is the primary mechanism for PML development. Risk factors for PML in Tysabri-treated patients include the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment. Patients must be enrolled in the restricted TOUCH Prescribing Program, which requires them to read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) document a range of neurological and systemic complaints in Tysabri users. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), fall (7,939 reports), memory impairment (7,895 reports), asthenia (7,852 reports), malaise (7,319 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and depression (3,091 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not establish causation, they reflect the spectrum of adverse experiences that may be associated with Tysabri therapy.
For patients in Washington who have developed PML after Tysabri use, attorney-related considerations involve the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure to Tysabri and documented harm can vary. The prescribing information notes that herpes encephalitis and meningitis cases have been reported with onset ranging from a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML itself typically occurs after prolonged Tysabri exposure, often beyond two years of therapy, but cases have been reported earlier, especially in patients with additional risk factors. The adequacy of warnings regarding Tysabri and PML is a central issue in potential litigation. The boxed warning clearly states the increased risk of PML and identifies specific risk factors. However, plaintiffs may argue that the warnings were insufficient to inform patients and healthcare providers of the true magnitude of risk, particularly in the context of the drug's mechanism and the difficulty of early PML diagnosis. The TOUCH program is designed to mitigate risk through mandatory education and monitoring, but its effectiveness in preventing PML has been questioned. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to evaluate the specific facts of their case, including the date of PML diagnosis, duration of Tysabri use, presence of risk factors, and any alleged failures in warning or monitoring. The statute of limitations clock typically starts at the time of diagnosis or when the patient reasonably should have known that Tysabri caused the injury. Prompt legal consultation is essential to preserve the right to seek compensation for medical expenses, lost income, pain and suffering, and other damages.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this typically starts at diagnosis or when the patient knew Tysabri caused the injury. Prompt legal consultation is crucial to preserve rights.
Risk factors include the presence of anti-JCV antibodies, longer duration of therapy (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.